Quintrio
Home

SERVICES-MEDICAL LABORATORIES

Caris Life Sciences, Inc. Common Stock

CAI

Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.

Last trade $20.21
Day change -$0.79 (-3.76%)
Day range $19.72 – $22.51
Volume 2,922,158
Market cap $6.02B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$6.02B
Price / earnings
62.69×
Price / book
9.42×
Price / sales
5.75×
EV / sales
5.49×
EV / EBITDA
35.4×

Profitability

Earnings per share
$0.33
Return on assets
7.65%
Return on equity
15.02%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.61×
Current ratio
6.71×
Quick ratio
5.84×
Cash ratio
4.19×

Cash flow

Price / cash flow
71.79×
Price / free cash flow
208.32×
Free cash flow
$28.91M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CAI, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q4 FY2015 Jun 30, 2015Q3 FY2015 Mar 31, 2015
Revenue$275.36M$263.71M$216.17M$292.89M$216.83M$181.4M$865.51M$817.8M
Cost of revenue$93.07M$84.12M$74.83M$71.97M$69.33M$67.71M$567.45M$542.84M
Gross profit$182.29M$179.6M$141.35M$220.91M$147.51M$113.69M$298.06M$274.96M
Selling, general and administrative$129.13M$120.31M$104.75M$100.66M$93.24M$106.63M$207M$205.17M
Research and development$33.84M$32.36M$31.32M$31.85M$21.62M$25.05M——
Total operating expenses$162.97M$152.67M$136.07M$132.5M$114.86M$131.67M$222.98M$221.24M
Operating income$19.32M$26.93M$5.28M$88.41M$32.64M-$17.99M$75.08M$53.72M
Interest expense-$9.25M-$9.23M-$12.81M-$11.36M-$13.51M-$19.21M-$8.61M-$8.47M
Income before taxes$16.87M-$614K-$644K$81.96M$24.33M-$71.79M$66.47M$45.24M
Income taxes$1.62M$23K-$134K$0$0$0$25.13M$16.19M
Net income$15.25M-$637K-$510K$81.96M$24.33M-$71.79M$41.35M$29.06M
Net income attributable to common shareholders$15.25M-$637K-$510K$81.96M$24.33M-$517.2M$41.38M$29.04M
EBITDA$25.92M$33.46M$10.35M$92.7M$37.51M-$11.58M$75.08M$69.78M
Basic earnings per share$0.05$0.00$0.00$0.29$0.09-$7.97$1.72$1.20
Diluted earnings per share$0.05$0.00$0.00$0.30$0.08-$7.97$1.68$1.18

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

BTSG vs. CAI: Which Stock Should Value Investors Buy Now?

In a comparison of two Medical Services sector stocks, BrightSpring Health Services (BTSG) emerges as the better value investment option compared to Caris Life Sciences (CAI). BTSG holds a Zacks Rank of #1 (Strong Buy) with a forward P/E of 35.08 and Value grade of B, while CAI has a Zacks Rank of #3 (Hold) with a forward P/E of 234.70 and Value grade of D. BTSG's superior earnings estimate revisions and more attractive valuation metrics make it the preferred choice for value investors.

Zacks Investment Research

Caris Life Sciences,?Inc. (CAI) Q3 Earnings and Revenues Top Estimates

Caris Life Sciences reported Q3 2026 earnings of $0.05 per share, beating consensus estimates of $0.03, with a 66.67% earnings surprise. Revenues reached $275.36 million, surpassing estimates by 9.75% and up from $216.83 million year-over-year. The company has beaten consensus estimates for four consecutive quarters. However, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.

Zacks Investment Research

Analysts Estimate Caris Life Sciences,?Inc. (CAI) to Report a Decline in Earnings: What to Look Out for

Caris Life Sciences (CAI) is expected to report a 62.5% year-over-year decline in earnings for Q3 2026 despite 15.7% revenue growth. With a negative Earnings ESP of -45.46% and Zacks Rank #3, the stock is not considered a compelling earnings-beat candidate. The company has beaten consensus estimates in the last four quarters, but recent analyst revisions suggest bearish sentiment on near-term earnings prospects.

Zacks Investment Research

Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?

Revvity shares surged 9.1% to $140.19 following upbeat commentary on AI-driven demand for research tools, improved order backlog, and a planned acquisition of Human Cell Design. The company expects quarterly EPS of $1.28 (+8.5% YoY) and revenues of $702.56M (+0.5% YoY). However, consensus EPS estimates have been marginally revised lower over the past 30 days, which could limit further price appreciation.

Benzinga

Stock Market Today: Nasdaq 100 Slips As Broadcom Plunges, Bitcoin Hits 4-Month Lows

The Nasdaq 100 fell 0.7% as chip stocks stumbled, with Broadcom cratering 15% despite beating earnings due to weak AI-chip revenue guidance. The Dow Jones rallied 1.7% on defensive and financial strength, while the S&P 500 remained flat. Bitcoin hit a 4-month low at $61,310. Other tech stocks like CrowdStrike, Ciena, and Five Below also declined despite beating estimates, reflecting a 'beat-and-bleed' market dynamic. Healthcare and financial stocks led gains.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Sep 9, 2021$0.30Sep 27, 2021recurring
Jun 9, 2021$0.30Jun 25, 2021recurring
Mar 10, 2021$0.30Mar 25, 2021recurring
Dec 8, 2020$0.25Dec 24, 2020recurring
Sep 10, 2020$0.25Sep 25, 2020recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.